Poster
Tumor Volume and T2 Hyperintensity Changes from DeFi: A Phase 3, Randomized, Controlled Trial of Nirogacestat in Patients With Desmoid Tumors
Author
Thierry Alcindor
Condition
desmoid tumors
Drug target
gamma-secretase
Source url
s3://convoke-optic-posters/2024-05-10/Alcindor_DeFi-Tumor-Volume-T2_2023-ASCO_Poster_FINAL.pdf
16 organizations
1 product
Product
NirogacestatOrganization
McGill University Health CenterOrganization
Memorial Sloan Kettering Cancer CenterOrganization
Netherlands Cancer InstituteOrganization
Duke Cancer InstituteOrganization
UCLA Jonsson Comprehensive Cancer CenterOrganization
PharPoint ResearchOrganization
Oregon Health & Science UniversityOrganization
Dana-Farber Cancer InstituteOrganization
University of HeidelbergOrganization
University of Colorado Anschutz Medical CampusOrganization
David Geffen School of Medicine at UCLAOrganization
MedpaceOrganization
SpringWorks TherapeuticsOrganization
University Hospitals Leuven, Leuven, BelgiumOrganization
Harvard Medical School